Ocular Therapeutix
OCUL
149 hedge funds and large institutions have $1.04B invested in Ocular Therapeutix in 2020 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 13 closing their positions.
315% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 13
246% more capital invested
Capital invested by funds: $301M → $1.04B (+$742M)
147% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $4.96M
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
38% more funds holding
Funds holding: 108 → 149 (+41)
37% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 35
3.8% more ownership
Funds ownership: 63.18% → 66.98% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.2M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$17.7M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$16.7M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$16.1M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$15.3M |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
-$11.1M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$8.12M |
| 5 |
DAM
Deltec Asset Management
New York
|
-$4.51M |
OCUL Hedge Fund Activity: Q4 2020 in Review
149 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2020, worth a combined $1.04B — up 246% from $301M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new OCUL positions and 13 closed out — a net gain of 41 holders — while 48 added to existing stakes and 35 trimmed.
The largest buyer was BlackRock, adding an estimated $21.2M. The largest seller was RA Capital Management, cutting an estimated $29.4M.
- 149 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2020, up from 108 in Q3 2020.
- Funds reported $1.04B of Ocular Therapeutix stock for Q4 2020, up 246% quarter-over-quarter.
- 54 funds opened new Ocular Therapeutix positions in Q4 2020 and 13 closed out, a net change of +41 holders.
- The largest Ocular Therapeutix buyer in Q4 2020 was BlackRock, an estimated $21.2M added.
- The largest Ocular Therapeutix seller in Q4 2020 was RA Capital Management, an estimated $29.4M sold.
Based on aggregated 13F filings for Q4 2020.